Clinical Trial: Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma

U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07328802) titled 'Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma' on June 19, 2025.

Brief Summary: Evaluation of Efficacy and Safety of Sintilimab Plus Bevacizumab and AG Regimen as First-Line Therapy in Patients with Surgically Ineligible Locally Advanced or Metastatic Cholangiocarcinoma

Objectives:

Primary Objective:

To assess the objective response rate (ORR) as per RECIST v1.1.

Secondary Objectives:

1. To evaluate the disease control rate (DCR) per RECIST v1.1.

2. To determine the duration of response (DOR) per RECIST v1.1.

3. To measure progression-...